This study is a single centre intervention study to compare two methods of determining the measured glomerular filtration rate (mGFR). Subjects who receive radioactively labeled iothalamate (125I) and hippuran (131I) within the framework of routine clinical care, will be co-administered iohexol. The primary trial endpoint is the mGFR when administered 125I-iothalamate and 131I-hippuran versus iohexol. By determining the mGFR using both iohexol and iothalamate in the same patients, a direct comparison of the two methods can be made in terms of their accuracy and precision. This makes it possible to determine the potential use of the non-radioactive measurement method as an alternative to the radioactive method and thus lower the overall radioactive burden for patients and personnel.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
208
Subjects will receive a single bolus of 5 mL of Omnipaque 300 (containing 3235 mg iohexol)
Subjects will receive 125I-iothalamate and 131I-hippuran as part of their routine clinical care.
University Medical Centre Groningen
Groningen, Netherlands
mGFR Iohexol
mGFR that is determined using the iohexol method
Time frame: Through study completion, an average of 1 year
mGFR Iothalamate and hippuran
mGFR that is determined using the warm 125I-iothalamate and 131I-hippuran method
Time frame: Through study completion, an average of 1 year
Repeated mGFR using iohexol on a separate study day
mGFR that is determined using the iohexol method
Time frame: Through study completion, an average of 1 year
Repeated mGFR using iothalamate and hippuran on a separate study day
mGFR that is determined using the warm 125I-iothalamate and 131I-hippuran method
Time frame: Through study completion, an average of 1 year
Secretariat Nephrology
CONTACT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.